Formycon operates as an independent biosimilars specialist with a scalable development platform covering ophthalmology, immunology, and chronic disease treatment. The company leverages an established infrastructure for biosimilar development from early-stage analysis through clinical testing and regulatory approval preparation.
Cyborg Score Rationale
Formycon demonstrates solid fundamentals as an established biosimilars specialist with approved commercial products and an expanding pipeline. However, the company remains unprofitable (EPS -$10.50) with modest revenue of $56.2M, limiting near-term upside and reflecting typical biotech execution risks.
Top Insights
Triple approved product portfolio focused on high-value indications including ophthalmology (ranibizumab, aflibercept) and immunology (ustekinumab)
Pipeline extends into immuno-oncology with pembrolizumab candidate and immunology programs (FYB208, FYB209)
Stock currently trading near analyst consensus target on relative valuation basis despite recent weakness
Company operates with complete control over biosimilar development value chain from early analysis through regulatory approval
Named Competitors
Biosimilar portfolio — Dominant global biosimilars player with broader portfolio
Biosimilar franchise — Large integrated biotech with biosimilar capabilities
Biosimilar offerings — Diversified pharma with growing biosimilar focus
Recent Developments
December 2025: Company maintains active commercial operations with approved biosimilars across multiple markets
2025: Continued portfolio expansion with immunology and immuno-oncology candidates in development
Open the full interactive Formycon AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.